Tuberculosis con resistencia a rifampicina

Abstract

Rifampicin-resistant tuberculosis (TB) (RR/MDR-TB) is a public health problem that hinders the tuberculosis elimination plan. There is a significant diagnostic gap associated with the limited global coverage of rapid molecular tests (RMT), which means that an important reservoir of community trans- mission persists. The success of therapies in these cases is also unsatisfactory, as it has high lethality and poor adherence to therapy regimens. A more extensive use of RMT for diagnosis and greater access to the new shortened therapies is necessary. Chile maintains active monitoring of drug susceptibility and widespread use of RMT as an initial diagnosis test, which, combined with the new shortened therapies with Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (BPLM scheme) promises better prospects for these patients.